Meet Donal O’Shea, CEO and Co-Founder of Pathology-Based Software Company: Deciphex

Deciphex is an Ireland-based software company focused on developing digital pathology-based software and services for clinical and research pathology. Our ambition is to connect and accelerate the world’s pathologists.

We believe that digital pathology combined with artificial intelligence will help pathologists work more efficiently, offering a solution to the outstanding challenges in supply/demand in pathology services. Deciphex plans to be at the forefront of this revolution with intelligently positioned solutions that address the biggest problems facing pathology today.

Deciphex (@Deciphex) / Twitter

How did the idea for Deciphex come about?

There were two aspects to this:

  • What gave me the idea was the dynamics of supply and demand in the pathology market. Deciphex is unique in that we truly understand the global supply and demand dynamics that exist in pathology services and how Digital Pathology and Artificial Intelligence can help with that. We understand the need to also work outside the company, in order to connect stakeholders to the support that will allow these services to be carried out.
  • Most organizations today struggle to find adequate coverage for pathology services, specifically within their own environment. The real pressing need in the market is to provide these organizations with access to additional external resources and digital pathology is a powerful tool in this regard. External capability in combination with AI can lead to highly efficient ways to fill any gaps in service delivery.

How has Deciphex evolved in the last two years?:

Deciphex was founded in 2017 and our initial market involvement was with the research community, our goal was to meet their specific needs and requirements regarding drug safety assessment.

The research community had a real need to provide connectivity between CRO and pharmaceutical companies in relation to peer-based digital pathology and primary review of safety studies. Over time, the big evolution has been the advent of our clinical services business, Diagnexia. Diagnexia is the only on-demand virtual pathology department.

Providing access to over 100 subspecialty pathologists for primary diagnostic and secondary consultation services. Diagnexia’s services help our customers to improve their response times, reducing their backlogs.

What can we expect from Deciphex in the future?:

Our goal is to establish a global network of pathology services and, in that context, to enable the largest available network of pathologists to support service needs. We look forward to scaling our network globally, allowing us to become the most extensive network of digital pathologists.

Along with the increased activities of this network with Artificial Intelligence for accelerated interpretation for decision support.

Leave a Comment